
    
      Approximately 16 participants are planned to be enrolled into the study. The study consists
      of 2 cohorts, and approximately 6 participants will be randomized to PF-06480605 and
      approximately 2 participants will be randomized to placebo in each cohort. Each participant
      will receive PF-06480605 or placebo subcutaneously.
    
  